BIOMAT Database Logo BIOMAT Database Logo

Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia transplanted with bone marrow from HLA-identical related donors. 1995

M Horstmann, and M Stockschläder, and H Kabisch, and A Zander

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006648 Histocompatibility The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts. HLA Incompatibility,Histoincompatibility,Human Leukocyte Antigen Incompatibility,Immunocompatibility,Tissue Compatibility,Compatibility, Tissue,HLA Incompatibilities,Histocompatibilities,Histoincompatibilities,Immunocompatibilities,Incompatibility, HLA,Tissue Compatibilities
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Cyclophosphamide and antithymocyte globulin conditioning may be sufficient for Korean patients with early stage severe aplastic anemia transplanted with marrow from donors other than HLA-identical siblings.
April 2001, Haematologica,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia.
June 1997, Bone marrow transplantation,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia.
December 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Bone marrow transplantation for severe aplastic anemia from HLA identical siblings.
January 1999, Haematologica,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
August 2004, Bone marrow transplantation,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: the experience from a single center.
January 2003, The hematology journal : the official journal of the European Haematology Association,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors.
June 1994, Blood,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Bone marrow transplantation (BMT) in children with severe aplastic anemia (SAA) from donors other than HLA identical siblings. EBMT Working Party on Severe Aplastic Anemia.
January 1991, Bone marrow transplantation,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings.
October 1989, Blood,
M Horstmann, and M Stockschläder, and H Kabisch, and A Zander
[Treatment of severe aplastic anemia with bone marrow transplants or with antithymocyte globulin. Evaluation of 27 patients].
February 1989, Revista clinica espanola,
Copied contents to your clipboard!